Predictors of Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank: Influence of Genetic and Nongenetic Factors

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2017-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1124/jpet.116.237594PMID 27815364PMCID PMC5193072
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CYP2A6 genotyping methods and strategies using real-time and end point PCR platforms.

  2016cited by this paper
• Genetic determinants of CYP2A6 activity across racial/ethnic groups with different risks of lung cancer and effect on their smoking intensity.

  2016cited by this paper
• Effects of the selected cytochrome P450 oxidoreductase genetic polymorphisms on cytochrome P450 2B6 activity as measured by bupropion hydroxylation

  2016influential reference
• Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response

  2016cited by this paper
• Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial.

  2015cited by this paper
• A Genome-Wide Association Study of a Biomarker of Nicotine Metabolism

  2015cited by this paper
• Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content

  2015cited by this paper
• Current developments of coumarin-based anti-cancer agents in medicinal chemistry.

  2015cited by this paper
• Nicotine Pharmacokinetics in Rats Is Altered as a Function of Age, Impacting the Interpretation of Animal Model Data

  2014cited by this paper
• Optimized Approaches for Quantification of Drug Transporters in Tissues and Cells by MRM Proteomics

  2014cited by this paper
• Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism.

  2014cited by this paper
• Identification of CYP3A7 for glyburide metabolism in human fetal livers.

  2014cited by this paper
• Variation in P450 oxidoreductase (POR) A503V and flavin-containing monooxygenase (FMO)-3 E158K is associated with minor alterations in nicotine metabolism, but does not alter cigarette consumption

  2014cited by this paper
• Known and Novel Sources of Variability in the Nicotine Metabolite Ratio in a Large Sample of Treatment-Seeking Smokers

  2014cited by this paper
• Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6).

  2014cited by this paper
• Genetic Variation in Aldo-Keto Reductase 1D1 (AKR1D1) Affects the Expression and Activity of Multiple Cytochrome P450s

  2013cited by this paper
• featureCounts: an efficient general purpose program for assigning sequence reads to genomic features

  2013cited by this paper
• TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions

  2013influential reference
• Pharmacogenetics of P450 oxidoreductase: implications in drug metabolism and therapy

  2012cited by this paper
• Differential analysis of gene regulation at transcript resolution with RNA-seq

  2012cited by this paper
• CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people

  2012cited by this paper
• A framework for variation discovery and genotyping using next-generation DNA sequencing data

  2011influential reference
• Determination of the nicotine metabolites cotinine and trans-3'-hydroxycotinine in biologic fluids of smokers and non-smokers using liquid chromatography-tandem mass spectrometry: biomarkers for tobacco smoke exposure and for phenotyping cytochrome P450 2A6 activity.

  2011cited by this paper
• Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk.

  2011cited by this paper
• Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors

  2010cited by this paper
• Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver.

  2010cited by this paper
• The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.

  2010influential reference
• Hepatic Cytochrome P450 Enzyme Alterations in Humans with Progressive Stages of Nonalcoholic Fatty Liver Disease The online version of this article (available at http://dmd.aspetjournals.org) contains supplemental material.

  2009cited by this paper
• In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function

  2009cited by this paper
• Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation.

  2009cited by this paper
• Genetic and environmental influences on the ratio of 3′hydroxycotinine to cotinine in plasma and urine

  2009cited by this paper
• Hepatic Cytochrome P 450 Enzyme Alterations in Humans with Progressive Stages of Nonalcoholic Fatty Liver Disease

  2009cited by this paper
• Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes

  2009cited by this paper
• Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study.

  2009cited by this paper
• Structure-activity relationships of human AKR-type oxidoreductases involved in bile acid synthesis: AKR1D1 and AKR1C4.

  2009cited by this paper
• Toward Personalized Therapy for Smoking Cessation: A Randomized Placebo‐controlled Trial of Bupropion

  2008cited by this paper
• Involvement of CYP2A6 in the Formation of a Novel Metabolite, 3-Hydroxypilocarpine, from Pilocarpine in Human Liver Microsomes

  2007cited by this paper
• Polypharmacy in elderly patients.

  2007cited by this paper
• Effects of dietary broccoli on human in vivo caffeine metabolism: a pilot study on a group of Jordanian volunteers.

  2007cited by this paper
• Genetic variability in CYP2A6 and the pharmacokinetics of nicotine.

  2007cited by this paper
• Human CYP2A6 Is Induced by Estrogen via Estrogen Receptor

  2007influential reference
• Female sex and oral contraceptive use accelerate nicotine metabolism

  2006influential reference
• Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.

  2006cited by this paper
• Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance

  2006cited by this paper
• Contribution of CYP 2 C 9 , CYP 2 A 6 , and CYP 2 B 6 to Valproic Acid Metabolism in Hepatic Microsomes from Individuals with the CYP 2 C 9 * 1 / * 1 Genotype

  2006cited by this paper
• Implications of CYP2A6 Genetic Variation for Smoking Behaviors and Nicotine Dependence

  2005cited by this paper
• The scientific case that nicotine is addictive

  2005cited by this paper
• Metabolism and Disposition Kinetics of Nicotine

  2005cited by this paper
• Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.

  2004cited by this paper
• Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity.

  2001influential reference
• Pharmacokinetics of nicotine in healthy elderly people

  2001cited by this paper
• Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays.

  2001cited by this paper
• Disrupted Bile Acid Homeostasis Reveals an Unexpected Interaction among Nuclear Hormone Receptors, Transporters, and Cytochrome P450*

  2001cited by this paper
• Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro.

  2000cited by this paper
• Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism

  2000cited by this paper
• Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction.

  1998cited by this paper
• A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes.

  1997cited by this paper
• Comparison of CYP2A6 catalytic activity on coumarin 7-hydroxylation in human and monkey liver microsomes

  1997cited by this paper
• Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers

  1993cited by this paper
• Isolation and characterization of a cytochrome P450 of the IIA subfamily from human liver microsomes.

  1991cited by this paper
• The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes.

  1990cited by this paper
• METABOLISM AND DISPOSITION

  1987cited by this paper
• A double‐blind, placebo‐controlled trial

  1986cited by this paper

• Pharmacokinetic Evaluation of a Cinnamon Product on CYP2A6 Substrate Drugs: Application of a Novel Tool Involving the Nicotine Metabolite Ratio.

  2026cites this paper
• Extending Investigations of miR‐126‐5p on the Regulation of CYP2A6, the Major Nicotine‐Inactivating Enzyme

  2025cites this paper
• Cytochrome P450 Family 4F2 and 4F11 Haplotype Mapping and Association with Hepatic Gene Expression and Vitamin K Hydroxylation Activity.

  2024cites this paper
• PharmVar GeneFocus: CYP2A6

  2024cites this paper
• Pharmacokinetics of Antibacterial Agents in the Elderly: The Body of Evidence

  2023cites this paper
• Gender Differences in Smoking Initiation and Cessation Associated with the Intergenerational Transfer of Smoking across Three Generations: The Nagahama Study

  2022cites this paper
• ProteoExcelTP: Development of a simple excel-based tool for surrogate peptide selection in mass spectrometry based targeted proteomics.

  2022cites this paper
• Quantitative Proteomics in Translational Absorption, Distribution, Metabolism, and Excretion and Precision Medicine

  2022cites this paper
• Nicotine metabolism and its association with CYP2A6 genotype among Indigenous people in Alaska who smoke

  2021cites this paper
• Functional characterization of novel rare CYP2A6 variants and potential implications for clinical outcomes

  2021cites this paper
• Tissue-Specific Proteomics Analysis of Anti-COVID-19 Nucleoside and Nucleotide Prodrug-Activating Enzymes Provides Insights into the Optimization of Prodrug Design and Pharmacotherapy Strategy

  2021cites this paper
• Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targeting CYP3A4*1G allele function

  2021cites this paper
• Cytochrome P450 2A6 is associated with macrophage polarization and is a potential biomarker for hepatocellular carcinoma

  2021cites this paper
• Ontogeny of Drug-Metabolizing Enzymes.

  2021cites this paper
• Mass spectrometry-based targeted proteomics method for the quantification of clinically relevant drug metabolizing enzymes in human specimens.

  2021cites this paper
• Emerging investigator series: human CYP2A6 catalyzes the oxidation of 6:2 fluorotelomer alcohol.

  2021cites this paper
• Quantitative Determination of Cytochrome P450 Using LC-MS/MS

  2021cites this paper
• How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?

  2020cites this paper
• Genetic polymorphisms of pharmacogenomic VIP variants in the Dai population from Yunnan province

  2020cites this paper
• Pharmacogenomics and Psychopharmacology

  2020cites this paper
• CHARACTERIZATION OF DIFFERENTIAL TISSUE ABUNDANCE OF MAJOR NON-CYP ENZYMES IN HUMAN.

  2020cites this paper
• Utility of Quantitative Proteomics for Enhancing the Predictive Ability of Physiologically Based Pharmacokinetic Models Across Disease States

  2020cites this paper
• Potential implications of DMET ontogeny on the disposition of commonly prescribed drugs in neonatal and pediatric intensive care units

  2020cites this paper
• From Genotype to Phenotype: Content and Activities of Cytochromes P450 2A6 in Human Liver In Vitro and Predicted In Vivo

  2019cites this paper
• Differences in the rate of nicotine metabolism among smokers with and without HIV.

  2019cites this paper
• Cancer Hazard Identification Integrating Human Variability: The Case of Coumarin

  2019influential citation
• Tobacco Smoke Exposure, Urban and Environmental Factors as Respiratory Disease Predictors in Italian Adolescents

  2019cites this paper
• Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6‐Mediated Metabolic Activity

  2019influential citation
• Biosignature Discovery for Substance Use Disorders Using Statistical Learning.

  2018cites this paper
• A Multifactorial Cytochrome P450 2D6 Genotype-Phenotype Prediction Model to Improve Precision of Clinical Pharmacogenomic Tests

  2018cites this paper
• Hepatic Abundance and Activity of Androgen- and Drug-Metabolizing Enzyme UGT2B17 Are Associated with Genotype, Age, and Sex

  2018cites this paper
• Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism

  2018cites this paper
• Genetic and Nongenetic Factors Associated with Protein Abundance of Flavin-Containing Monooxygenase 3 in Human Liver

  2017cites this paper
• The Promises of Quantitative Proteomics in Precision Medicine.

  2017cites this paper
• Variation in CYP2A6 Activity and Personalized Medicine

  2017cites this paper
• Association of Secondhand Tobacco Smoke and Abdominal Adiposity in the United States Population

  2016cites this paper